DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Traboulsee A, Greenberg B, Bennett JL. , et al.
A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as monotherapy for patients with neuromyelitis optica spectrum disorder (NMOSD).
ECTRIMS Online Library 2019;
2018 (229118): 1278
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.